Fig. 4From: Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the NetherlandsScatter plot of ICERs from the undiscounted probabilistic sensitivity analysis. PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life-year; WTP, willingness to payBack to article page